PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
09-Feb-2021 Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug into Clinical Trials Businesswire
09-Feb-2021 Global CRISPR Gene Editing Market (2020 to 2030) - Focus on Products, Applications, End-users, Country Data and Competitive Landscape - ResearchAndMarkets.com Businesswire
09-Feb-2021 UCL offers Minimally-Invasive Master’s in Aesthetics (MS) for prescribing pharmacists UCL
09-Feb-2021 Metrion Biosciences Appoints John Montana as Non-Executive Director Businesswire
09-Feb-2021 Janssen Announces Treatment with ERLEADA®▼(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Businesswire
09-Feb-2021 武田2020财年第三季度业绩彰显增长加速和持续的韧性;确认了2020财年全年管理层指引,并上调了自由现金流以及列报每股盈利的预测 Businesswire
09-Feb-2021 武田2020會計年度第三季業績顯示成長加速和持續的韌性;確認了2020會計年度全年管理層指引,並調高對自由現金流以及列報每股盈餘的預測 Businesswire
09-Feb-2021 Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL Businesswire
08-Feb-2021 Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer Businesswire
08-Feb-2021 Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and Prevention of COVID-19 Businesswire
08-Feb-2021 Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma Businesswire
08-Feb-2021 Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial Businesswire
08-Feb-2021 Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium Businesswire
08-Feb-2021 Ipsen: New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx® in Combination with Opdivo® Showed Significantly Improved QoL Benefits and Sustained Superior Efficacy Versus sunitinib in Patients Living with aRCC Businesswire
08-Feb-2021 OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial Businesswire
08-Feb-2021 Ipsen : L’étude CheckMate-9ER évaluant Cabometyx® associé à Opdivo® dans le RCC a montré une amélioration significative de la qualité de vie et confirmé une efficacité supérieure par rapport au sunitinib Businesswire
08-Feb-2021 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET Businesswire
08-Feb-2021 Ironwood Pharmaceuticals Announces CEO Transition Businesswire
08-Feb-2021 U.S. FDA Grants Breakthrough Device Designation to Vascular Perfusion Solutions for its Visionary VP.S Encore™ Cardiac Transport Device Businesswire
08-Feb-2021 Genprex Announces Formation of Clinical Advisory Board Businesswire